1. Market Research
  2. > All Companies
  3. > Biogen, Inc. - Product Pipeline Review - 2015

Biogen, Inc. - Product Pipeline Review - 2015

  • April 2015
  • -
  • Global Markets Direct
  • -
  • 86 pages

Biogen, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Biogen, Inc. - Product Pipeline Review - 2015’, provides an overview of the Biogen, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biogen, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biogen, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biogen, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Biogen, Inc.’s pipeline products

Reasons to buy

- Evaluate Biogen, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biogen, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biogen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biogen, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biogen, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Biogen, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Biogen, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Biogen, Inc. Snapshot 7
Biogen, Inc. Overview 7
Key Information 7
Key Facts 7
Biogen, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Biogen, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Biogen, Inc. - Pipeline Products Glance 18
Biogen, Inc. - Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Biogen, Inc. - Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Biogen, Inc. - Early Stage Pipeline Products 22
Preclinical Products/Combination Treatment Modalities 22
Biogen, Inc. - Drug Profiles 23
antihemophilic factor (recombinant), fc fusion protein 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
natalizumab 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
rituximab 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
aducanumab 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
BG-00010 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
BIIB-023 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
opicinumab 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
STX-100 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Antibodies to Activate BCAD2 for Systematic Lupus Erthematosus 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
BG-00001 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
BIIB-059 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
BIIB-061 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
5D-10 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
BIIB-053 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
BIIB-054 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Gene Therapy for Hemophilia A and B 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Monoclonal Antibodies to Inhibit Alpha Synuclein for Neurodegenerative Diseases 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Monoclonal Antibody to Inhibit TDP-43 for Neurodegenerative Diseases 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
NI-105 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
NI-205 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Recombinant Protein to Agonize GM-CSFR for Alzheimer's disease and Brain Injury 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Recombinant Protein to Replace Factor VIII for Hemophilia A 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Small Molecules to Activate Glucosylceramidase for Parkinson's Disease 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Biogen, Inc. - Pipeline Analysis 55
Biogen, Inc. - Pipeline Products by Target 55
Biogen, Inc. - Pipeline Products by Route of Administration 57
Biogen, Inc. - Pipeline Products by Molecule Type 58
Biogen, Inc. - Pipeline Products by Mechanism of Action 59
Biogen, Inc. - Recent Pipeline Updates 61
Biogen, Inc. - Dormant Projects 73
Biogen, Inc. - Discontinued Pipeline Products 75
Discontinued Pipeline Product Profiles 75
baminercept alfa 75
clenoliximab 75
CNF-1010 75
dexpramipexole dihydrochloride 75
naxifylline 76
Biogen, Inc. - Company Statement 77
Biogen, Inc. - Locations And Subsidiaries 79
Head Office 79
Other Locations and Subsidiaries 79
Biogen, Inc. - Key Manufacturing Facilities 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables
Biogen, Inc., Key Information 7
Biogen, Inc., Key Facts 7
Biogen, Inc. - Pipeline by Indication, 2015 9
Biogen, Inc. - Pipeline by Stage of Development, 2015 11
Biogen, Inc. - Monotherapy Products in Pipeline, 2015 12
Biogen, Inc. - Partnered Products in Pipeline, 2015 13
Biogen, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 14
Biogen, Inc. - Out-Licensed Products in Pipeline, 2015 16
Biogen, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 17
Biogen, Inc. - Pre-Registration, 2015 18
Biogen, Inc. - Phase III, 2015 19
Biogen, Inc. - Phase II, 2015 20
Biogen, Inc. - Phase I, 2015 21
Biogen, Inc. - Preclinical, 2015 22
Biogen, Inc. - Pipeline by Target, 2015 56
Biogen, Inc. - Pipeline by Route of Administration, 2015 57
Biogen, Inc. - Pipeline by Molecule Type, 2015 58
Biogen, Inc. - Pipeline Products by Mechanism of Action, 2015 60
Biogen, Inc. - Recent Pipeline Updates, 2015 61
Biogen, Inc. - Dormant Developmental Projects,2015 73
Biogen, Inc. - Discontinued Pipeline Products, 2015 75
Biogen, Inc., Other Locations 79
Biogen, Inc., Subsidiaries 80
Biogen, Inc., Key Manufacturing Facilities 84

List of Figures
Biogen, Inc. - Pipeline by Top 10 Indication, 2015 9
Biogen, Inc. - Pipeline by Stage of Development, 2015 11
Biogen, Inc. - Monotherapy Products in Pipeline, 2015 12
Biogen, Inc. - Partnered Products in Pipeline, 2015 13
Biogen, Inc. - Out-Licensed Products in Pipeline, 2015 16
Biogen, Inc. - Pipeline by Top 10 Target, 2015 55
Biogen, Inc. - Pipeline by Top 10 Route of Administration, 2015 57
Biogen, Inc. - Pipeline by Top 10 Molecule Type, 2015 58
Biogen, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 59

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Sleep Apnea Diagnostic Systems - Pipeline Review, 2015

Sleep Apnea Diagnostic Systems - Pipeline Review, 2015

  • $ 2 500
  • Company report
  • July 2015
  • by Global Data

Sleep Apnea Diagnostic Systems - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Sleep Apnea Diagnostic Systems - Pipeline Review, 2015" provides an overview of Sleep Apnea ...

Parkinson%s Disease - Pipeline Review, H1 2015

Parkinson%s Disease - Pipeline Review, H1 2015

  • $ 2 500
  • Company report
  • June 2015
  • by Global Markets Direct

Parkinson's Disease - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Parkinson's Disease - Pipeline Review, H1 2015’, provides an overview of the Parkinson's Disease’s therapeutic pipeline. ...

Multiple Sclerosis - Pipeline Review, H1 2015

Multiple Sclerosis - Pipeline Review, H1 2015

  • $ 2 500
  • Company report
  • June 2015
  • by Global Markets Direct

Multiple Sclerosis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Multiple Sclerosis - Pipeline Review, H1 2015’, provides an overview of the Multiple Sclerosis’s therapeutic pipeline. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.